MXPA06004657A - Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia. - Google Patents

Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.

Info

Publication number
MXPA06004657A
MXPA06004657A MXPA06004657A MXPA06004657A MXPA06004657A MX PA06004657 A MXPA06004657 A MX PA06004657A MX PA06004657 A MXPA06004657 A MX PA06004657A MX PA06004657 A MXPA06004657 A MX PA06004657A MX PA06004657 A MXPA06004657 A MX PA06004657A
Authority
MX
Mexico
Prior art keywords
alkyl
group
phenyl
inhibitor
cancer
Prior art date
Application number
MXPA06004657A
Other languages
English (en)
Spanish (es)
Inventor
Thomas D Penning
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA06004657A publication Critical patent/MXPA06004657A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06004657A 2003-10-28 2004-10-28 Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia. MXPA06004657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51502103P 2003-10-28 2003-10-28
PCT/US2004/035949 WO2005041879A2 (fr) 2003-10-28 2004-10-28 Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie

Publications (1)

Publication Number Publication Date
MXPA06004657A true MXPA06004657A (es) 2006-06-27

Family

ID=34549367

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06004657A MXPA06004657A (es) 2003-10-28 2004-10-28 Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.

Country Status (6)

Country Link
EP (1) EP1682143A2 (fr)
JP (1) JP2007509968A (fr)
BR (1) BRPI0415896A (fr)
CA (1) CA2543503A1 (fr)
MX (1) MXPA06004657A (fr)
WO (1) WO2005041879A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954083B2 (ja) 2004-11-18 2012-06-13 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ９０活性を調節するトリアゾール化合物
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
WO2006097459A1 (fr) * 2005-03-14 2006-09-21 Nycomed Gmbh Procede de prevention des maladies cardiovasculaires
CA2700893A1 (fr) * 2007-10-12 2009-04-16 Arqule, Inc. Composes substitutes du tetrazole et leurs utilisations
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CA2724413C (fr) * 2008-05-15 2016-10-18 Duke University Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2384752A1 (fr) * 2010-04-14 2011-11-09 Universitätsklinikum Hamburg-Eppendorf Préparation de combinaison contenant un inhibiteur de phosphodiestérase et un inhibiteur de COX destinée au traitement du cancer
EP2560640A1 (fr) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
CA2853806C (fr) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Polytherapie d'inhibiteurs de hsp 90 avec des agents contenant du platine
CA2853799A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Therapie anticancereuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomerase i
CA2854188A1 (fr) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Association therapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
CN103102306A (zh) * 2013-02-06 2013-05-15 河南东泰制药有限公司 一种塞来昔布的制备方法
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
CN105492444B (zh) 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
CN104069113B (zh) * 2014-07-08 2016-08-31 山东大学齐鲁医院 西地那非在制备治疗抗血管瘤的药物中的应用
CA3125353A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction menine-mll
JP2022516057A (ja) 2018-12-31 2022-02-24 バイオメア フュージョン，エルエルシー メニン－ｍｌｌ相互作用の不可逆的阻害剤
CN112679470B (zh) * 2021-01-06 2023-01-13 中国药科大学 (e)-1-苯基4-烯基-1h-吡唑类化合物及其医药用途
EP4387972A1 (fr) 2021-08-20 2024-06-26 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidine-6-yl]phényl]-4-[[3(r)-[(1-oxo-2-propène-1-yl)amino]-1-pipéridinyl]méthyl]-2-pyridinecarboxamide, un inhibiteur irréversible de ménine-mll pour le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
WO2002094196A2 (fr) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Methode de traitement de cancers associes a des niveaux de her-2 eleves
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

Also Published As

Publication number Publication date
EP1682143A2 (fr) 2006-07-26
WO2005041879A2 (fr) 2005-05-12
JP2007509968A (ja) 2007-04-19
BRPI0415896A (pt) 2007-01-09
WO2005041879A3 (fr) 2005-10-06
CA2543503A1 (fr) 2005-05-12

Similar Documents

Publication Publication Date Title
US20040147581A1 (en) Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
MXPA06004657A (es) Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
WO2005044194A2 (fr) Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
WO2005048942A2 (fr) Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
US20040204472A1 (en) Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2472199A1 (fr) Compositions et procedes de traitement comprenant des agonistes gamma du recepteur active du proliferateur du peroxysome et des inhibiteurs selectifs de la cyclooxygenase 2.
EP1725222A2 (fr) Procedes et compositions pour le traitement ou la prevention de troubles psychiatriques avec des inhibiteurs de cox-2 seuls et en combinaison avec des antidepresseurs
CA2474016A1 (fr) Traitement du rhume et de la toux par combinaison d'un inhibiteur selectif de la cyclooxygenase-2 et d'un principe actif contre le rhume et la toux, et compositions renfermant ces substances
US20030212138A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030157061A1 (en) Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
CA2542277A1 (fr) Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci
CA2457452A1 (fr) Compositions destinees au traitement et a la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et d'un sulfate de chondroitine
US20040053900A1 (en) Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
CA2457453A1 (fr) Compositions assurant le traitement et la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et de glucosamine
EP1611095A2 (fr) Procede d'administration de steroide a un niveau benefique avec un inhibiteur de la cyclo-oxygenase-2 et compositions correspondantes
KR20040083478A (ko) 시클로옥시게나제-2 선택성 억제제 및 아스피린의조합물을 이용한 통증, 염증 및 염증-관련 장애의 치료
WO2005020926A2 (fr) Traitement ou prevention de troubles vasculaires au moyen d'inhibiteurs de cox-2 associee a des inhibiteurs de la phosphodiesterase specifique de l'amp cyclique
MXPA05006489A (es) Metodo para usar un inhibidor de la cox-2 y un inhibidor de la topoisomerasa ii como terapia de combinacion en el tratamiento de la neoplasia.
US20050187172A1 (en) Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
US20050004224A1 (en) Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
KR20040063112A (ko) 시클로옥시게나제-2 선택성 억제제 및 글루코사민을이용한 통증 및 염증의 치료 및 예방을 위한 조성물

Legal Events

Date Code Title Description
FA Abandonment or withdrawal